Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics, Inc. develops clinical-stage therapies for oncology and central nervous system disorders. Company news centers on NDV-01, an intravesical sustained-release gemcitabine-docetaxel therapy being evaluated for non-muscle invasive bladder cancer, including clinical data, FDA feedback on registrational study design, and presentations at medical conferences.
Recurring updates also cover quarterly and annual financial results, business progress, healthcare conference participation, and financing activity tied to the company’s clinical development plans.
Relmada Therapeutics, Inc. provided a corporate update and reported first-quarter 2024 financial results, highlighting advancements in their Phase 3 programs for major depressive disorder treatment. They plan to commence a Phase 1 trial for modified-release psilocybin in obese patients. Financially, research and development expenses decreased, general and administrative expenses lowered, and net cash used in operating activities declined. The net loss was reduced, with the company holding approximately $83.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024.
Relmada Therapeutics, Inc. (RLMD) will release its first quarter financial results on May 8, 2024, followed by a conference call and webcast discussing the results and corporate updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.